公开(公告)号：EP3345615B1

公开(公告)日：2019-10-16

申请号：EP17172199.6

申请日：2011-03-01

申请人： Bayer Healthcare LLC

发明人： Scholz, Peter ,  Wang, Zhuozhi ,  PAN, Junliang ,  Grudzinska, Joanna ,  Votsmeier, Christian ,  Tebbe, Jan ,  Birkenfeld, Jörg ,  Wobst, Nina ,  Brückner, Simone ,  Steinig, Susanne

IPC分类号： A61K39/00 ,  C07K16/38 ,  A61P7/04

公开(公告)号：EP3345615A1

公开(公告)日：2018-07-11

申请号：EP17172199.6

申请日：2011-03-01

申请人： Bayer Healthcare LLC

发明人： Scholz, Peter ,  Wang, Zhuozhi ,  PAN, Junliang ,  Grudzinska, Joanna ,  Votsmeier, Christian ,  Tebbe, Jan ,  Birkenfeld, Jörg ,  Wobst, Nina ,  Brückner, Simone ,  Steinig, Susanne

IPC分类号： A61K39/00 ,  C07K16/38 ,  A61P7/04

摘要： Monoclonal antibodies to human tissue factor pathway inhibitor (TFPI) are provided. Further provided are the isolated nucleic acid molecules encoding the same. Pharmaceutical compositions comprising the anti-TFPI monoclonal antibodies and methods of treatment of genetic and acquired deficiencies or defects in coagulations such as hemophilia A and B are also described. Also described are methods for shortening the bleeding time by administering an anti-TFPI monoclonal antibody to a patient in need thereof. Methods for producing a monoclonal antibody that binds human TFPI according to the present invention are also provided.
In some embodiments, the monoclonal antibodies to TFPI provided have been optimized, for example to have increased affinity or increased functional activity.